Variant sequences: the new frontier in sequence IP

A variant sequence is typically a naturally-occurring molecule, most frequently protein, which has been modified in order to impart desired characteristics such as improved stability under anticipated use conditions, or increased activity. Optimising sequences and, of course, the associated IP rights, span most areas of biotechnology.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

INTA: ‘New normal’ for in-house counsel as budgets fall

16 March 2026 Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.

Americas

Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks

12 March 2026 The event unpacked how technology, litigation trends, and global events are adding complexity while also offering benefits for legal teams under pressure to reduce costs.

Americas

Astellas blocks generic version of key urology drug until 2030

12 March 2026 The pharma company has successfully enforced its patents against Ascent’s proposed mirabegron copy, shortly after inking licensing deals elsewhere over the medication.

More features

Emotional Perception: What next for patent holders?

Novo battles for GLP-1 leadership with fresh lawsuit and slashed prices

Generic rival blocked as AZ defends diabetes stronghold

The curtain closes on three major drug disputes

Novartis takes aim at Tafinlar generic in latest suit

Fed Circ overturns PTAB decision in $83.4m DNA case

Novartis win blocks generics relitigating $7.8bn heart drug patent

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Variant sequences: the new frontier in sequence IP

More on this story

Editor's picks

Editor's picks

More features